Japan's Nikkei falls as tech shares track Wall Street losses
By Kevin Buckland
TOKYO, Nov 18 (Reuters) -Japan's Nikkei share average fell on Monday as technology shares tracked U.S peers' losses at the end of last week, while drugmaker shares declined after a noted vaccine sceptic was appointed to head the U.S. Department of Health.
Automaker shares came under pressure from an overall stronger yen, although the currency pulled back slightly from early highs after Bank of Japan Governor Kazuo Ueda refrained from giving strong hints about the timing of interest rate hikes in a speech to business leaders. Ueda will also hold a news conference at 0445 GMT.
The Nikkei .N225 entered the midday recess down 0.78% at 38,343.39.
It had earlier tumbled as much as 1.27%, but got some respite after the yen dropped back to the weaker side of 155 per dollar JPY=EBS from as strong as 153.84 earlier in the session. It was changing hands at 154.60 as of 0233 GMT.
A strong yen reduces the value of overseas revenue for Japan's heavyweight exporters, and also makes Japanese stocks more expensive for foreign investors.
The broader Topix .TOPX lost 0.47%.
On Friday, all three of the main Wall Street indexes declined, and the Philadelphia SE Semiconductor Index .SOX slumped 3.4%.
The initial euphoria over a Donald Trump election win ushering in easier regulation and bigger fiscal spending shifted last week to worries over the potential for higher inflation under his policies that could slow Federal Reserve rate cuts.
His cabinet picks have also caused some concerns, including the appointment of Robert F Kennedy Jr, who has spread misinformation on vaccines, to head the Department of Health and Human Services.
Chugai Pharmaceutical 4519.T was the Nikkei's biggest loser, sliding 8.56%. Drugmakers as a group .IPHAM.T led decliners among the Tokyo Stock Exchange's 33 industry groups.
"Whether the Trump trade is over or just on pause is not possible to discern at the moment," said Kazuo Kamitani, an equities strategist at Nomura Securities.
"My personal feeling is that the market will be turbulent all of this month."
Among tech names, Tokyo Electron 8035.T dropped 2.26% and startup investor SoftBank Group 9984.T fell 2.31%.
Nvidia supplier Advantest 6857.T was volatile, dropping as much as 3.58% before bouncing as much as 1.38% and then entering the midday recess close to flat. Nvidia's earnings report on Wednesday will be one of the most closely watched market events of the week.
Toyota Motor 7203.T and Nissan Motor 7201.T each fell about 1%.
Reporting by Kevin Buckland; Editing by Janane Venkatraman
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
